Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- GSK Investigational Site · Brooksville, FL
- GSK Investigational Site · Plantation, FL
Kansas · 1
- GSK Investigational Site · Kansas City, KS
Missouri · 1
- GSK Investigational Site · St Louis, MO
New Jersey · 1
- GSK Investigational Site · New Brunswick, NJ
New York · 1
- GSK Investigational Site · New York, NY
Pennsylvania · 2
- GSK Investigational Site · DuBois, PA
- GSK Investigational Site · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.